Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2020-08-28

AUTHORS

Daniel J. Landsburg, Alexa Koike, Sunita D. Nasta, Jakub Svoboda, Stephen J. Schuster, Mariusz A. Wasik, Gabriel C. Caponetti

ABSTRACT

Given the poor prognosis of MYC-overexpressing diffuse large B cell lymphoma (DLBCL) and B cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt lymphoma/high grade B cell lymphoma (BCLU/HGBL), and preclinical data suggesting that MYC may regulate the antitumor immune response, we sought to characterize expression of immune checkpoint proteins on tumor tissue from patients diagnosed with these lymphomas. Immunohistochemical staining for immune checkpoint protein expression was applied to 56 cases of MYC-overexpressing DLBCL and BCLU/HGBL, 35 of which also harbored MYC rearrangement (MYC-R). Analysis revealed both frequent overexpression of immune checkpoint proteins as well as differences in overexpression patterns based upon MYC-R status, with MYC-R cases more likely to overexpress PD-L1 and PD-1 in the tumor microenvironment (50 vs. 15%, p = 0.02 and 32 vs. 5%, p = 0.02, respectively) but less likely to overexpress CTLA-4 and CD80 on tumor cells (34 vs. 71%, p = 0.01 and 34 vs. 81%, p = 0.001, respectively), as compared to cases without MYC-R. These data may suggest a biologic rationale for investigation of the effect of checkpoint inhibitor therapies in these subgroups of MYC-overexpressing DLBCL and BCLU/HGBL. More... »

PAGES

869-874

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00262-020-02708-3

DOI

http://dx.doi.org/10.1007/s00262-020-02708-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1130397345

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32857184


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Regulation, Neoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genes, myc", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immune Checkpoint Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, B-Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Pennsylvania, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "University of Pennsylvania, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Landsburg", 
        "givenName": "Daniel J.", 
        "id": "sg:person.01227167744.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227167744.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pennsylvania, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "University of Pennsylvania, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koike", 
        "givenName": "Alexa", 
        "id": "sg:person.016034737203.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016034737203.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pennsylvania, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "University of Pennsylvania, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nasta", 
        "givenName": "Sunita D.", 
        "id": "sg:person.01001105007.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001105007.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pennsylvania, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "University of Pennsylvania, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Svoboda", 
        "givenName": "Jakub", 
        "id": "sg:person.0722677225.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722677225.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pennsylvania, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "University of Pennsylvania, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schuster", 
        "givenName": "Stephen J.", 
        "id": "sg:person.011060364477.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011060364477.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Fox Chase Cancer Center and University of Pennsylvania, Philadelphia, USA", 
          "id": "http://www.grid.ac/institutes/grid.249335.a", 
          "name": [
            "Fox Chase Cancer Center and University of Pennsylvania, Philadelphia, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wasik", 
        "givenName": "Mariusz A.", 
        "id": "sg:person.01157554301.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157554301.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pennsylvania, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "University of Pennsylvania, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Caponetti", 
        "givenName": "Gabriel C.", 
        "id": "sg:person.01103471633.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103471633.20"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11899-016-0320-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028178341", 
          "https://doi.org/10.1007/s11899-016-0320-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40880-017-0262-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099676706", 
          "https://doi.org/10.1186/s40880-017-0262-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2017.103", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084128334", 
          "https://doi.org/10.1038/leu.2017.103"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41379-018-0193-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111569928", 
          "https://doi.org/10.1038/s41379-018-0193-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-08-28", 
    "datePublishedReg": "2020-08-28", 
    "description": "Given the poor prognosis of MYC-overexpressing diffuse large B cell lymphoma (DLBCL) and B cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt lymphoma/high grade B cell lymphoma (BCLU/HGBL), and preclinical data suggesting that MYC may regulate the antitumor immune response, we sought to characterize expression of immune checkpoint proteins on tumor tissue from patients diagnosed with these lymphomas. Immunohistochemical staining for immune checkpoint protein expression was applied to 56 cases of MYC-overexpressing DLBCL and BCLU/HGBL, 35 of which also harbored MYC rearrangement (MYC-R). Analysis revealed both frequent overexpression of immune checkpoint proteins as well as differences in overexpression patterns based upon MYC-R status, with MYC-R cases more likely to overexpress PD-L1 and PD-1 in the tumor microenvironment (50 vs. 15%, p\u2009=\u20090.02 and 32 vs. 5%, p\u2009=\u20090.02, respectively) but less likely to overexpress CTLA-4 and CD80 on tumor cells (34 vs. 71%, p\u2009=\u20090.01 and 34 vs. 81%, p\u2009=\u20090.001, respectively), as compared to cases without MYC-R. These data may suggest a biologic rationale for investigation of the effect of checkpoint inhibitor therapies in these subgroups of MYC-overexpressing DLBCL and BCLU/HGBL.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00262-020-02708-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096240", 
        "issn": [
          "0340-7004", 
          "1432-0851"
        ], 
        "name": "Cancer Immunology, Immunotherapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "70"
      }
    ], 
    "keywords": [
      "immune checkpoint proteins", 
      "immune checkpoint protein expression", 
      "checkpoint protein expression", 
      "cell lymphoma", 
      "high grade B cell lymphoma", 
      "cell non-Hodgkin lymphoma", 
      "checkpoint inhibitor therapy", 
      "antitumor immune response", 
      "protein expression", 
      "non-Hodgkin lymphoma", 
      "PD-L1", 
      "inhibitor therapy", 
      "PD-1", 
      "poor prognosis", 
      "preclinical data", 
      "CTLA-4", 
      "biologic rationale", 
      "immune response", 
      "immunohistochemical staining", 
      "lymphoma", 
      "MYC rearrangement", 
      "tumor tissue", 
      "frequent overexpression", 
      "tumor microenvironment", 
      "tumor cells", 
      "overexpression pattern", 
      "DLBCL", 
      "HGBL", 
      "Myc", 
      "checkpoint proteins", 
      "expression", 
      "CD80", 
      "prognosis", 
      "patients", 
      "therapy", 
      "cases", 
      "staining", 
      "subgroups", 
      "protein", 
      "tissue", 
      "microenvironment", 
      "overexpression", 
      "status", 
      "diffuse", 
      "cells", 
      "response", 
      "rationale", 
      "patterns", 
      "data", 
      "differences", 
      "effect", 
      "investigation", 
      "analysis", 
      "features", 
      "rearrangement", 
      "Burkitt lymphoma/high grade B cell lymphoma", 
      "lymphoma/high grade B cell lymphoma", 
      "grade B cell lymphoma", 
      "B cell lymphoma", 
      "cases of MYC", 
      "BCLU/HGBL", 
      "subgroups of MYC"
    ], 
    "name": "Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas", 
    "pagination": "869-874", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1130397345"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00262-020-02708-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32857184"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00262-020-02708-3", 
      "https://app.dimensions.ai/details/publication/pub.1130397345"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_844.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00262-020-02708-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00262-020-02708-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00262-020-02708-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00262-020-02708-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00262-020-02708-3'


 

This table displays all metadata directly associated to this object as RDF triples.

273 TRIPLES      22 PREDICATES      114 URIs      102 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00262-020-02708-3 schema:about N002b1412a37d4b47bcfcc19cf9efb916
2 N1c8a9fb8fabd44b0a4fdfc91216ec8c6
3 N2301e5efad6d4043886d615ab539bfbc
4 N33f39be1c45f46b39563e4e8240ff0a1
5 N4652cd23af45428eb5cc0f5fa00b7a22
6 N4a486bea22cb46e4bfdb864129565a2e
7 N6bb647dcb3be44f4a09cd1844cfcfb79
8 N75de3228cc6144f1ba6f1becc83fce23
9 N7c180ca88261458bb60d2943c84457dc
10 N84bc464cabe7418f8dad03d92dc2258b
11 N8c01cd0ad77242d1a87fd3e08e003f4e
12 N9cffb5d4cab84aff8c8857e756b76c02
13 Naf90124961e846d4ac9f394ebbc0915f
14 Nbad2ae9e541341a792bef28512627f80
15 Nc2bd1fe34be94604a6ee93cac1247b22
16 Nc7f3263e20c04cc697b8c08bbf4eebd6
17 Nc9a09380ef704735b6237d6838b1eb58
18 Nd416a29059324f9db673ae142d24c7fe
19 Nded97d22838b4a078854fbeb3c208fe8
20 Ne6a086d5e70749848ee2a9727a0cdc4d
21 Nf3119c94d27449039c15ad94463b58b3
22 Nf82689d01f6348d298d62978a1f1ecae
23 anzsrc-for:11
24 anzsrc-for:1112
25 schema:author N5102a70abbfe40db8a168eb49969f57a
26 schema:citation sg:pub.10.1007/s11899-016-0320-7
27 sg:pub.10.1038/leu.2017.103
28 sg:pub.10.1038/s41379-018-0193-5
29 sg:pub.10.1186/s40880-017-0262-z
30 schema:datePublished 2020-08-28
31 schema:datePublishedReg 2020-08-28
32 schema:description Given the poor prognosis of MYC-overexpressing diffuse large B cell lymphoma (DLBCL) and B cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt lymphoma/high grade B cell lymphoma (BCLU/HGBL), and preclinical data suggesting that MYC may regulate the antitumor immune response, we sought to characterize expression of immune checkpoint proteins on tumor tissue from patients diagnosed with these lymphomas. Immunohistochemical staining for immune checkpoint protein expression was applied to 56 cases of MYC-overexpressing DLBCL and BCLU/HGBL, 35 of which also harbored MYC rearrangement (MYC-R). Analysis revealed both frequent overexpression of immune checkpoint proteins as well as differences in overexpression patterns based upon MYC-R status, with MYC-R cases more likely to overexpress PD-L1 and PD-1 in the tumor microenvironment (50 vs. 15%, p = 0.02 and 32 vs. 5%, p = 0.02, respectively) but less likely to overexpress CTLA-4 and CD80 on tumor cells (34 vs. 71%, p = 0.01 and 34 vs. 81%, p = 0.001, respectively), as compared to cases without MYC-R. These data may suggest a biologic rationale for investigation of the effect of checkpoint inhibitor therapies in these subgroups of MYC-overexpressing DLBCL and BCLU/HGBL.
33 schema:genre article
34 schema:inLanguage en
35 schema:isAccessibleForFree false
36 schema:isPartOf N4fa29a117e604feebc8f8128fa24b70c
37 N8b67c5018cda4af69d773ba0f79f2933
38 sg:journal.1096240
39 schema:keywords B cell lymphoma
40 BCLU/HGBL
41 Burkitt lymphoma/high grade B cell lymphoma
42 CD80
43 CTLA-4
44 DLBCL
45 HGBL
46 MYC rearrangement
47 Myc
48 PD-1
49 PD-L1
50 analysis
51 antitumor immune response
52 biologic rationale
53 cases
54 cases of MYC
55 cell lymphoma
56 cell non-Hodgkin lymphoma
57 cells
58 checkpoint inhibitor therapy
59 checkpoint protein expression
60 checkpoint proteins
61 data
62 differences
63 diffuse
64 effect
65 expression
66 features
67 frequent overexpression
68 grade B cell lymphoma
69 high grade B cell lymphoma
70 immune checkpoint protein expression
71 immune checkpoint proteins
72 immune response
73 immunohistochemical staining
74 inhibitor therapy
75 investigation
76 lymphoma
77 lymphoma/high grade B cell lymphoma
78 microenvironment
79 non-Hodgkin lymphoma
80 overexpression
81 overexpression pattern
82 patients
83 patterns
84 poor prognosis
85 preclinical data
86 prognosis
87 protein
88 protein expression
89 rationale
90 rearrangement
91 response
92 staining
93 status
94 subgroups
95 subgroups of MYC
96 therapy
97 tissue
98 tumor cells
99 tumor microenvironment
100 tumor tissue
101 schema:name Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas
102 schema:pagination 869-874
103 schema:productId N461e69a986ad4ee1bb5b1c5a16044f33
104 N605ba446748b42c8afd946c16eb6b777
105 Nd0ba5a7926c34de6832c3c4159279223
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1130397345
107 https://doi.org/10.1007/s00262-020-02708-3
108 schema:sdDatePublished 2022-01-01T18:55
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher N25e7ca6084704bccb9f5a042e6563a6e
111 schema:url https://doi.org/10.1007/s00262-020-02708-3
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N002b1412a37d4b47bcfcc19cf9efb916 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Gene Expression Regulation, Neoplastic
117 rdf:type schema:DefinedTerm
118 N1c8a9fb8fabd44b0a4fdfc91216ec8c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Vincristine
120 rdf:type schema:DefinedTerm
121 N2301e5efad6d4043886d615ab539bfbc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Aged
123 rdf:type schema:DefinedTerm
124 N25e7ca6084704bccb9f5a042e6563a6e schema:name Springer Nature - SN SciGraph project
125 rdf:type schema:Organization
126 N33f39be1c45f46b39563e4e8240ff0a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Prognosis
128 rdf:type schema:DefinedTerm
129 N40186e3df2b043058ed1926f3870e849 rdf:first sg:person.011060364477.44
130 rdf:rest N4fd8c374e3ee45b08065bf7fae4b2b1e
131 N461e69a986ad4ee1bb5b1c5a16044f33 schema:name dimensions_id
132 schema:value pub.1130397345
133 rdf:type schema:PropertyValue
134 N4652cd23af45428eb5cc0f5fa00b7a22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Biomarkers, Tumor
136 rdf:type schema:DefinedTerm
137 N4a486bea22cb46e4bfdb864129565a2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Rituximab
139 rdf:type schema:DefinedTerm
140 N4fa29a117e604feebc8f8128fa24b70c schema:issueNumber 3
141 rdf:type schema:PublicationIssue
142 N4fd8c374e3ee45b08065bf7fae4b2b1e rdf:first sg:person.01157554301.24
143 rdf:rest Na57866df385040779d30146606c8a3f8
144 N5102a70abbfe40db8a168eb49969f57a rdf:first sg:person.01227167744.96
145 rdf:rest Nfe7fb5d56e56450b9e09976953745d50
146 N605ba446748b42c8afd946c16eb6b777 schema:name doi
147 schema:value 10.1007/s00262-020-02708-3
148 rdf:type schema:PropertyValue
149 N6bb647dcb3be44f4a09cd1844cfcfb79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Adult
151 rdf:type schema:DefinedTerm
152 N72039e4713864fd794555de5c815b59e rdf:first sg:person.0722677225.98
153 rdf:rest N40186e3df2b043058ed1926f3870e849
154 N73a444c8bfa84f099cb9fbbb5d8a792a rdf:first sg:person.01001105007.49
155 rdf:rest N72039e4713864fd794555de5c815b59e
156 N75de3228cc6144f1ba6f1becc83fce23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Male
158 rdf:type schema:DefinedTerm
159 N7c180ca88261458bb60d2943c84457dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Prednisone
161 rdf:type schema:DefinedTerm
162 N84bc464cabe7418f8dad03d92dc2258b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Genes, myc
164 rdf:type schema:DefinedTerm
165 N8b67c5018cda4af69d773ba0f79f2933 schema:volumeNumber 70
166 rdf:type schema:PublicationVolume
167 N8c01cd0ad77242d1a87fd3e08e003f4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Middle Aged
169 rdf:type schema:DefinedTerm
170 N9cffb5d4cab84aff8c8857e756b76c02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Cyclophosphamide
172 rdf:type schema:DefinedTerm
173 Na57866df385040779d30146606c8a3f8 rdf:first sg:person.01103471633.20
174 rdf:rest rdf:nil
175 Naf90124961e846d4ac9f394ebbc0915f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Humans
177 rdf:type schema:DefinedTerm
178 Nbad2ae9e541341a792bef28512627f80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Neoplasm Staging
180 rdf:type schema:DefinedTerm
181 Nc2bd1fe34be94604a6ee93cac1247b22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Recurrence
183 rdf:type schema:DefinedTerm
184 Nc7f3263e20c04cc697b8c08bbf4eebd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Lymphoma, B-Cell
186 rdf:type schema:DefinedTerm
187 Nc9a09380ef704735b6237d6838b1eb58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Female
189 rdf:type schema:DefinedTerm
190 Nd0ba5a7926c34de6832c3c4159279223 schema:name pubmed_id
191 schema:value 32857184
192 rdf:type schema:PropertyValue
193 Nd416a29059324f9db673ae142d24c7fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Treatment Outcome
195 rdf:type schema:DefinedTerm
196 Nded97d22838b4a078854fbeb3c208fe8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Immune Checkpoint Proteins
198 rdf:type schema:DefinedTerm
199 Ne6a086d5e70749848ee2a9727a0cdc4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Survival Analysis
201 rdf:type schema:DefinedTerm
202 Nf3119c94d27449039c15ad94463b58b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Antineoplastic Combined Chemotherapy Protocols
204 rdf:type schema:DefinedTerm
205 Nf82689d01f6348d298d62978a1f1ecae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Doxorubicin
207 rdf:type schema:DefinedTerm
208 Nfe7fb5d56e56450b9e09976953745d50 rdf:first sg:person.016034737203.37
209 rdf:rest N73a444c8bfa84f099cb9fbbb5d8a792a
210 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
211 schema:name Medical and Health Sciences
212 rdf:type schema:DefinedTerm
213 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
214 schema:name Oncology and Carcinogenesis
215 rdf:type schema:DefinedTerm
216 sg:journal.1096240 schema:issn 0340-7004
217 1432-0851
218 schema:name Cancer Immunology, Immunotherapy
219 schema:publisher Springer Nature
220 rdf:type schema:Periodical
221 sg:person.01001105007.49 schema:affiliation grid-institutes:grid.25879.31
222 schema:familyName Nasta
223 schema:givenName Sunita D.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001105007.49
225 rdf:type schema:Person
226 sg:person.01103471633.20 schema:affiliation grid-institutes:grid.25879.31
227 schema:familyName Caponetti
228 schema:givenName Gabriel C.
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103471633.20
230 rdf:type schema:Person
231 sg:person.011060364477.44 schema:affiliation grid-institutes:grid.25879.31
232 schema:familyName Schuster
233 schema:givenName Stephen J.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011060364477.44
235 rdf:type schema:Person
236 sg:person.01157554301.24 schema:affiliation grid-institutes:grid.249335.a
237 schema:familyName Wasik
238 schema:givenName Mariusz A.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157554301.24
240 rdf:type schema:Person
241 sg:person.01227167744.96 schema:affiliation grid-institutes:grid.25879.31
242 schema:familyName Landsburg
243 schema:givenName Daniel J.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227167744.96
245 rdf:type schema:Person
246 sg:person.016034737203.37 schema:affiliation grid-institutes:grid.25879.31
247 schema:familyName Koike
248 schema:givenName Alexa
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016034737203.37
250 rdf:type schema:Person
251 sg:person.0722677225.98 schema:affiliation grid-institutes:grid.25879.31
252 schema:familyName Svoboda
253 schema:givenName Jakub
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722677225.98
255 rdf:type schema:Person
256 sg:pub.10.1007/s11899-016-0320-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028178341
257 https://doi.org/10.1007/s11899-016-0320-7
258 rdf:type schema:CreativeWork
259 sg:pub.10.1038/leu.2017.103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084128334
260 https://doi.org/10.1038/leu.2017.103
261 rdf:type schema:CreativeWork
262 sg:pub.10.1038/s41379-018-0193-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111569928
263 https://doi.org/10.1038/s41379-018-0193-5
264 rdf:type schema:CreativeWork
265 sg:pub.10.1186/s40880-017-0262-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1099676706
266 https://doi.org/10.1186/s40880-017-0262-z
267 rdf:type schema:CreativeWork
268 grid-institutes:grid.249335.a schema:alternateName Fox Chase Cancer Center and University of Pennsylvania, Philadelphia, USA
269 schema:name Fox Chase Cancer Center and University of Pennsylvania, Philadelphia, USA
270 rdf:type schema:Organization
271 grid-institutes:grid.25879.31 schema:alternateName University of Pennsylvania, Philadelphia, PA, USA
272 schema:name University of Pennsylvania, Philadelphia, PA, USA
273 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...